Q1 Loss Hits $90.1M for REGENXBIO, But Key Drug RGX-202 Shows Safety and Purity, Cash to 2027
RGNX is trading near its 52-week low of $6.015 (4.6% above the low) on elevated volume (10× avg).
Summary
REGENXBIO reported a Q1 net loss of $90.1 million, driven by a lack of prior-year license revenue and reduced Zolgensma royalties. The company also provided an updated cash runway, extending into early 2027. Crucially, new data for its RGX-202 trial showed a favorable safety profile with two resolved serious adverse events and over 80% full capsid purity.
This news provides specific financial figures and clinical details that were broadly summarized in the company's 10-Q filing on May 14th, which mentioned a "large Q1 loss" and "highly positive Phase III results" for RGX-202. The $90.1 million loss is significant for a company of this size, but the extended cash runway offers some liquidity clarity, potentially easing prior "going concern" doubts. The specific positive safety and purity data for RGX-202 are vital for its continued development, reinforcing the positive Phase III results and building confidence in the drug's profile. Investors will now focus on further clinical milestones for RGX-202 and the company's long-term financial strategy.
At the time of this announcement, RGNX was trading at $6.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $322.3M. The 52-week trading range was $6.02 to $16.19. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.